To view the PDF file, sign up for a MySharenet subscription.

ASCENDIS HEALTH LIMITED - Trading Statement

Release Date: 07/09/2016 07:30
Code(s): ASC     PDF:  
Wrap Text
Trading Statement

ASCENDIS HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2008/005856/06)
Share code: ASC ISIN: ZAE000185005
(“Ascendis” or “the Company”)

TRADING STATEMENT

In terms of paragraph 3.4(b) of the JSE Limited’s Listings Requirements, Ascendis shareholders are
hereby advised that the Company’s financial results for the twelve months ended 30 June 2016 are
expected to be more than a 20% change from the previous corresponding period.

The table below illustrates the ranges anticipated against the comparative period:

                                             12 months            12 months          % increase/
                                             ended                ended              (decrease)
                                             30 June 2016         30 June 2015

 Normalised Headline Earnings                R325m – R336m        R245m              33% – 37%

 Normalised Headline Earnings per share      116 – 121 cents      93 cents           25% – 30%
 (“NHEPS”)
 Basic Earnings                              R151m – R163m        R210m              (28)% – (22)%

 Basic Earnings per share (“EPS”)            54 – 59 cents        80 cents           (33)% – (26)%

 Headline Earnings                           R147m – R158m        R209m              (30)% - (24)%

 Headline Earnings per share (“HEPS”)        52 – 57 cents        79 cents           (34)% - (28)%



Notes:
   1.  Normalised headline earnings comprise basic earnings adjusted for specific non-trading items
       and once-off costs. Once off costs amounted to c.R150m, representing c.2% of the purchase
       consideration of the Remedica and Scitec acquisitions as announced on SENS on 26 August
       2016 (“Acquisitions”) and are mainly due to the transaction costs pertaining to these
       Acquisitions. The earnings of the Acquisitions will only be accounted for in the next financial
       year, which explains the discrepancy and subsequent decrease in basic and headline
       earnings as well as the EPS and HEPS.
   2.  NHEPS comprises normalised headline earnings per share adjusted for specific non-trading
       items and once off costs as indicated in point (1) above.
   3.  The “per share” measures reflect a lower percentage increase than the earnings numbers due
       to the change in weighted average number of shares of c.5m being an increase of c.2%, due
       to additional shares issued by Ascendis during the course of the twelve month period.


The financial information on which this trading statement is based has not been reviewed or reported
on by the Company’s auditors.

Shareholders are advised that the results for the twelve months ended 30 June 2016 are scheduled to
be released on SENS on 14 September 2016 and presented in Johannesburg on 14 September 2016
and Cape Town on 15 September 2016.

7 September 2016
Johannesburg

Sponsor
Investec Bank Limited

Date: 07/09/2016 07:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story